| Drug General Information |
| Drug ID |
D08VCI
|
| Former ID |
DNC000779
|
| Drug Name |
Ifenprodil
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer pain [ICD9: 140-229, 338,780; ICD10:R52, G89]
|
Withdrawn from market |
[1],
[2]
|
|---|
| Therapeutic Class |
Analgesics
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H27NO2
|
| InChI |
InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
|
| InChIKey |
UYNVMODNBIQBMV-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4725773, 8152332, 14752941, 24262973, 26751765, 29215029, 29222812, 47811044, 47960032, 49698431, 50016323, 50104451, 50104452, 53788156, 57321942, 77542351, 81041086, 85213187, 85787500, 90341159, 92308801, 96024756, 103856535, 103983044, 104304238, 118313765, 123121346, 124749897, 124886924, 124960908, 125345551, 126645206, 129438974, 134339686, 134339687, 135048478, 135697523, 137004977, 142433824, 144204466, 152034593, 162174615, 162222110, 163414206, 164786771, 170465791, 170485605, 172913925, 178102121, 179150197
|
| SuperDrug ATC ID |
C04AX28
|
| SuperDrug CAS ID |
cas=023210562
|
| Target and Pathway |
| Target(s) |
Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Antagonist |
[3]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Glutamatergic synapse
|
|
Dopaminergic synapse
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Huntington's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholism
|
|
Systemic lupus erythematosus
|
|
PANTHER Pathway
|
Huntington disease
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
Reelin signaling pathway
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
BDNF signaling pathway
|
| References |
| REF 1 | Effects of the novel 5-hydroxytryptamine reuptake inhibitor indalpine and ethanol on psychomotor performance. Arzneimittelforschung. 1988 Jan;38(1):98-102. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5472). |
|---|
| REF 3 | NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250. Epub 2009 Apr 21. |
|---|
